Geode Capital Management LLC Buys 76,661 Shares of Stoke Therapeutics, Inc. (NASDAQ:STOK)

Geode Capital Management LLC increased its stake in shares of Stoke Therapeutics, Inc. (NASDAQ:STOK) by 9.7% in the 3rd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 870,831 shares of the company’s stock after purchasing an additional 76,661 shares during the period. Geode Capital Management LLC owned approximately 1.64% of Stoke Therapeutics worth $10,705,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in the stock. Quest Partners LLC purchased a new stake in Stoke Therapeutics during the 2nd quarter valued at $29,000. Zurcher Kantonalbank Zurich Cantonalbank purchased a new position in shares of Stoke Therapeutics in the 2nd quarter worth $123,000. Intech Investment Management LLC bought a new stake in shares of Stoke Therapeutics in the third quarter worth $160,000. The Manufacturers Life Insurance Company increased its position in Stoke Therapeutics by 16.7% during the second quarter. The Manufacturers Life Insurance Company now owns 13,964 shares of the company’s stock valued at $189,000 after acquiring an additional 1,994 shares during the last quarter. Finally, Mesirow Financial Investment Management Inc. bought a new position in Stoke Therapeutics in the third quarter valued at about $192,000.

Analysts Set New Price Targets

A number of equities research analysts have issued reports on the company. Leerink Partnrs upgraded Stoke Therapeutics to a “strong-buy” rating in a research note on Friday, October 11th. Cantor Fitzgerald restated an “overweight” rating on shares of Stoke Therapeutics in a research report on Tuesday, December 10th. Leerink Partners started coverage on shares of Stoke Therapeutics in a research report on Monday, October 14th. They issued an “outperform” rating and a $18.00 price target on the stock. Needham & Company LLC reissued a “buy” rating and set a $22.00 price objective on shares of Stoke Therapeutics in a research report on Wednesday, November 6th. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $35.00 target price on shares of Stoke Therapeutics in a report on Wednesday, November 6th. One equities research analyst has rated the stock with a hold rating, eight have assigned a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Buy” and an average price target of $21.29.

Insider Buying and Selling

In other news, insider Barry Ticho sold 13,945 shares of Stoke Therapeutics stock in a transaction that occurred on Friday, December 6th. The shares were sold at an average price of $12.78, for a total transaction of $178,217.10. Following the sale, the insider now owns 47,332 shares in the company, valued at $604,902.96. This trade represents a 22.76 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, CEO Edward M. Md Kaye sold 6,786 shares of the company’s stock in a transaction on Monday, December 9th. The stock was sold at an average price of $12.99, for a total transaction of $88,150.14. Following the transaction, the chief executive officer now owns 61,885 shares of the company’s stock, valued at approximately $803,886.15. This represents a 9.88 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 62,849 shares of company stock worth $809,421. 11.30% of the stock is owned by corporate insiders.

Stoke Therapeutics Price Performance

Shares of NASDAQ STOK opened at $11.03 on Wednesday. The stock has a market cap of $584.23 million, a PE ratio of -5.25 and a beta of 0.95. Stoke Therapeutics, Inc. has a 1 year low of $4.09 and a 1 year high of $17.58. The firm has a fifty day moving average price of $12.25 and a 200-day moving average price of $13.28.

Stoke Therapeutics (NASDAQ:STOK) last issued its quarterly earnings results on Tuesday, November 5th. The company reported ($0.47) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.52) by $0.05. The business had revenue of $4.89 million during the quarter, compared to analyst estimates of $3.46 million. Stoke Therapeutics had a negative return on equity of 54.45% and a negative net margin of 629.90%. On average, research analysts expect that Stoke Therapeutics, Inc. will post -2.03 EPS for the current year.

About Stoke Therapeutics

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.